ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients

Study ID
STU 102017-020

Study Sites

  • Children’s Medical Center (Dallas, Plano, Southlake)

Brittany Glass-Thomas

Principal Investigator
Daniel Bowers, M.D.


Primary: To estimate the progression-free survival (PFS) of children >= 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor bed of 36 Gy for a tot

Participant Eligibility